Estela Rodriguez, Associate Director of Community Outreach in Thoracic Oncology at the University of Miami’s Sylvester Comprehensive Cancer Center, shared a post on X:
“Best of ASCO: SCLC and Early Stage NSCLC ASCO26 Abstracts presented by Ana I. Velázquez Mañana.
- LIBRETTO-432: Adjuvant selpercatinib dramatically reduced recurrence risk in resected RET+ NSCLC and is poised to become a new standard of care.
- ALCHEMIST: Adjuvant nivolumab did not improve DFS in resected EGFR/ALK–wild-type NSCLC. ( includes all PDL1s, delayed adjuvant tx)
- Delphi304: Tarlatamab: Demonstrated meaningful intracranial activity and improved outcomes in relapsed SCLC patients with brain metastases. – current standard in 2nd line Lung Cancer.”
Other articles featuring Estela Rodriguez on OncoDaily.